Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tazemetostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 known ✓ | Q15910 | 20/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.99 |
| ▸ | EED | O75530 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.99 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.99 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.99 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.99 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.99 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.99 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.99 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tazemetostat SCHEMBL15313373 | 1.00 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL29350231 | 0.99 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13276848 | 0.99 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13277005 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL16653521 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276853 | 0.97 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL31087432 | 0.97 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL31087436 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13277447 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276541 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250161478-A1 | LINKER PAYLOADS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2025-05-22 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4392036-A1 | SELECTIVE ISONITRILE INHIBITORS OF CYTOCHROME P450 SUBTYPES | Brandeis University (US) | 2024-07-03 | — | — | EP | claimed |
| EP-4294453-A1 | LINKER-PAYLOADS AND CONJUGATES THEREOF | Glykos Finland Oy (FI) | 2023-12-27 | — | — | EP | claimed |
| WO-2023230233-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2023220192-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | FOUNDATION MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| WO-2022175595-A1 | LINKER-PAYLOADS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2022-08-25 | — | — | WO | claimed |
| US-20260146294-A1 | METHODS TO ENRICH NUCLEOTIDE VARIANTS BY NEGATIVE SELECTION | GUARDANT HEALTH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260148802-A1 | DETERMINING CELLULAR PHENOTYPES INDICATIVE OF A CONDITION BASED ON FRAGMENTOMIC FEATURES | FOUNDATION MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260148823-A1 | DETERMINING CONDITION SUBTYPE BASED ON FRAGMENTOMIC FEATURES | FOUNDATION MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2022058871-A1 | SOLID FORMS OF A CDK4 INHIBITOR | PFIZER INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220090175-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022018667-A1 | COMBINATION THERAPIES USING CDK2 AND CDC25A INHIBITORS | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022018596-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146294-A1 | METHODS TO ENRICH NUCLEOTIDE VARIANTS BY NEGATIVE SELECTION | NSUN2, NOP2, ADAR | EZH2 3055/4885NR1I2 4052/4885EED 2838/4885 |
| US-20250161478-A1 | LINKER PAYLOADS AND CONJUGATES THEREOF | PAICS, CD47, CD44 | EZH2 697/4885NR1I2 4230/4885EED 2097/4885 |
| US-20260148823-A1 | DETERMINING CONDITION SUBTYPE BASED ON FRAGMENTOMIC FEATURES | BRCA1, BCR, FGFR2 | EZH2 2263/4885NR1I2 1228/4885EED 4438/4885 |
| US-20260148802-A1 | DETERMINING CELLULAR PHENOTYPES INDICATIVE OF A CONDITION BASED ON FRAGMENTOMIC FEATURES | UPF1, ILF3, ZFP3 | EZH2 1883/4885NR1I2 1292/4885EED 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.